Cargando…

T110. CLINICAL CHARACTERISTICS OF FORMAL THOUGHT DISORDER IN SCHIZOPHRENIA

BACKGROUND: Our study aimed to present the distinctive correlates of formal thought disorder in patients with schizophrenia, using the Clinical Language Disorder Rating Scale (CLANG) METHODS: We compared the formal thought disorder and other clinical characteristics between schizophrenia patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Euijin, Park, Jong-Ik, Jung, Han-Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Session III
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234618/ http://dx.doi.org/10.1093/schbul/sbaa029.670

Ejemplares similares

S91. CLINICAL CHARACTERISTICS OF FORMAL THOUGHT DISORDER IN SCHIZOPHRENIA
por: Choi, Joonho, et al.
Publicado: (2018)

T226. PSYCHOMETRIC INVESTIGATION OF SELF-REPORTED THOUGHT DISORDER IN NON-CLINICAL SAMPLES
por: Sumner, Philip, et al.
Publicado: (2020)

M96. A NEW ASSESSMENT TOOL FOR FORMAL THOUGHT DISORDER IN SCHIZOPHRENIA: DOKUZ EYLUL THOUGHT DISORDER SCALE
por: Yalincetin, Berna, et al.
Publicado: (2020)

T16. SCHIZOPHRENIA SPECTRUM DISORDER: DEPRESSION TRAJECTORIES AND IMMUNE MARKERS
por: Hoprekstad, Gunnhild, et al.
Publicado: (2020)

T194. SUBJECTIVE ANOMALIES OF IMAGINATION AGGREGATE IN SCHIZOPHRENIA-SPECTRUM DISORDERS AND ARE ASSOCIATED WITH DISORDERS OF BASIC SELF
por: Rosén Rasmussen, Andreas, et al.
Publicado: (2020)

T62. A COMPUTATIONAL ANALYSIS OF MOTIVATIONAL DEFICITS IN SCHIZOPHRENIA SPECTRUM DISORDERS
por: Waltz, James, et al.
Publicado: (2020)

T73. COGNITIVE CLUSTERING IN SCHIZOPHRENIA SPECTRUM DISORDER AND THE ASSOCIATION WITH BRAIN VOLUME
por: Oomen, Priscilla, et al.
Publicado: (2020)

S54. THE RELATION OF FORMAL THOUGHT DISORDER WITH COGNITIVE FUNCTIONS, GLOBAL AND SOCIAL FUNCTIONING AND QUALITY OF LIFE IN PATIENTS WITH SCHIZOPHRENIA
por: Mutlu, Emre, et al.
Publicado: (2020)

T216. VARIATION IN SIDE EFFECTS TO ANTIPSYCHOTIC TREATMENT ACROSS SCHIZOPHRENIA SPECTRUM DISORDERS
por: Susanne Neumeier, Maria, et al.
Publicado: (2020)

T196. THERAPEUTIC MANAGEMENT IN MULTIPLE SCLEROSIS AND SCHIZOPHRENIA SPECTRUM DISORDERS DUAL DIAGNOSIS
por: Vasiliu, Octavian
Publicado: (2020)

T98. CHARACTERIZING THE CLINICAL COURSE IN SCHIZOPHRENIA WITH DIGITAL PHENOTYPING
por: Torous, John, et al.
Publicado: (2020)

T27. COGNITIVE RESERVE IN CHILD AND ADOLESCENT OFFSPRING OF PATIENTS DIANOSED WITH SCHIZOPHRENIA OR BIPOLAR DISORDER
por: De la Serna, Elena, et al.
Publicado: (2020)

T86. RELEVANCE OF CANNABIS USE AS A PREDICTOR OF CLINICAL OUTCOME IN FIRST-EPISODE SCHIZOPHRENIA SPECTRUM DISORDER PATIENTS OVER 24 MONTHS OF TREATMENT
por: Scheffler, Frederika, et al.
Publicado: (2020)

T169. SEMANTIC PROCESSING IN RELATION TO ANATOMICAL INTEGRITY OF THE VENTRAL LANGUAGE STREAM IN SCHIZOPHRENIA SPECTRUM DISORDERS
por: Surbeck, Werner, et al.
Publicado: (2020)

T195. PSYCHOTIC DISORDERS IN PATIENTS WHO USE SYNTHETIC CANNABINOIDS: CLINICAL CHARACTERISTICS AND PATIENT PROFILE
por: Skriabin, Valentin, et al.
Publicado: (2020)

T15. MISMATCH NEGATIVITY INDICES AS A PROGNOSTIC FACTOR FOR REMISSION IN SCHIZOPHRENIA
por: Shim, Se-Hoon, et al.
Publicado: (2020)

Formal Thought Disorder and Working Memory Deficit in Schizophrenia
por: Mishra, Sumitra, et al.
Publicado: (2022)

T185. OLIGOPEPTIDASES IN SCHIZOPHRENIA
Publicado: (2020)

T241. INCIDENCE AND SOCIO-DEMOGRAPHIC/CLINICAL CHARACTERISTICS OF PSYCHOTIC DISORDERS IN INDIA, NIGERIA AND TRINIDAD: PRELIMINARY BASELINE FINDINGS FROM INTREPID II
por: Roberts, Tessa, et al.
Publicado: (2020)

T190. COMPARABILITY OF PATIENT AND STUDY CHARACTERISTICS IN RANDOMIZED CONTROLLED TRIALS ON PHARMACOTHERAPY AND PSYCHOTHERAPY FOR POSITIVE SYMPTOMS OF SCHIZOPHRENIA: A SYSTEMATIC REVIEW
Publicado: (2020)

T26. VISUO-TACTILE TRANSFER AND AUDIO-VISUAL INTEGRATION IMPAIRMENT AS A NEW VULNERABILITY MARKER IN CHILDREN-AT-RISK OF SCHIZOPHRENIA, BIPOLAR DISORDER OR RECURRENT DEPRESSIVE DISORDER
por: Roy, Martin, et al.
Publicado: (2020)

T201. EFFECTS OF PALIPERIDONE PALMITATE ON HEALTHCARE UTILIZATION AND COSTS FOR PATIENTS WITH SCHIZOPHRENIA: A CLAIM-BASED MIRROR-IMAGE STUDY IN SOUTH KOREA
por: Hun Jung, Myung, et al.
Publicado: (2020)

T173. POLYGENETIC RISK SCORES FOR MAJOR PSYCHIATRIC DISORDERS AMONG SCHIZOPHRENIA PATIENTS, THEIR FIRST-DEGREE RELATIVES AND HEALTHY SUBJECTS
por: Ohi, Kazutaka, et al.
Publicado: (2020)

T69. CORRELATION BETWEEN PERFORMANCE-BASED AND INTERVIEW-BASED COGNITIVE MEASUREMENTS IN PATIENTS WITH SCHIZOPHRENIA
por: Jeon, Dong-wook, et al.
Publicado: (2020)

T77. ASSOCIATION BETWEEN INTRACELLULAR INFECTIOUS AGENTS AND SCHIZOPHRENIA
por: Kwon, Young-Joon, et al.
Publicado: (2020)

T92. POSSIBLE COMBINATIONS OF DSM-IV AND DSM-5 CRITERIA IN SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER VERSUS MAJOR DEPRESSIVE AND MANIC EPISODES
por: Kontis, Dimitrios, et al.
Publicado: (2020)

T59. ACOUSTIC SPEECH MARKERS FOR SCHIZOPHRENIA
por: de Boer, Janna, et al.
Publicado: (2020)

T60. GENETIC INFLUENCES ON MEMORY FUNCTIONS AND RELATED BRAIN STRUCTURES AND ASSOCIATIONS WITH SCHIZOPHRENIA SPECTRUM DISORDERS: A NATION-WIDE TWIN STUDY
por: Lemvigh, Cecilie, et al.
Publicado: (2020)

T188. THE CLINICAL SCIENCE OF TRANSCRANIAL DIRECT CURRENT STIMULATION STUDIES IN SCHIZOPHRENIA: SYSTEMATIC REVIEW AND META-ANALYSIS
por: Mervis, Joshua, et al.
Publicado: (2020)

T205. LUMATEPERONE IN THE TREATMENT OF SCHIZOPHRENIA: EVALUATION OF EXTRAPYRAMIDAL AND MOTOR SYMPTOMS IN 4 LATE-PHASE CLINICAL TRIALS
por: Durgam, Suresh, et al.
Publicado: (2020)

T37. PREPULSE INHIBITION IN UNAFFECTED SIBLINGS OF SCHIZOPHRENIA AND CLINICAL-HIGH RISK WITHOUT FAMILY HISTORY OF PSYCHOSIS
por: Zhen, Mao, et al.
Publicado: (2020)

T186. IMPACT OF A STRUCTURED VALIDATED FAMILY PSYCHOEDUCATIONAL PROGRAM (PROFAMILLE) ON MENTAL HEALTH CARE OF PEOPLE WITH SCHIZOPHRENIA SPECTRUM DISORDERS: PRELIMINARY RESULTS
por: Bralet, Marie-Cécile, et al.
Publicado: (2020)

T176. INSIGHTS INTO THE ROLE OF ORAL AND GUT MICROBIOME IN THE PATHOGENESIS OF SCHIZOPHRENIA
por: Ghorbani, Mahin, et al.
Publicado: (2020)

T2. ADVERSE CHILDHOOD EXPERIENCES IN PEOPLE WITH SCHIZOPHRENIA
por: Klaunig, Mallory, et al.
Publicado: (2020)

T90. QUANTIFYING THE CORE DEFICIT IN CLASSICAL SCHIZOPHRENIA
por: Rathnaiah, Mohanbabu, et al.
Publicado: (2020)

T197. TREATMENT STRATEGIES FOR ULTRA-RESISTANT SCHIZOPHRENIAS
por: Vasiliu, Octavian
Publicado: (2020)

T11. CORONARY ARTERY CALCIFICATION IN PEOPLE WITH SCHIZOPHRENIA
por: Trab, Trine, et al.
Publicado: (2020)

T227. VIRTUAL REALITY SOCIAL SKILLS TRAINING IMPROVES SOCIAL ATTENTION IN INDIVIDUALS WITH SCHIZOPHRENIA
por: Torregrossa, Lénie, et al.
Publicado: (2020)

T211. COMPARISON OF REHOSPITALIZATION RATE IN INDIVIDUALS WITH SCHIZOPHRENIA CHANGED FROM PALIPERIDONE PALMITATE TO ORAL ANTIPSYCHOTICS
por: Ju Lee, Bong, et al.
Publicado: (2020)

T19. GLUTAMATE AND RESPONSE TO CLOZAPINE IN TREATMENT RESISTANT SCHIZOPHRENIA
por: Egerton, Alice, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pgehp50onvir7kf2vohcq7kecu